Skip to Main Content

A majority of pharmaceutical executives in Canada say new regulations designed to cut prescription drug spending by the Canadian government are delaying product launches and R&D investment and will subsequently hurt employment, according to a new survey sponsored by an industry trade group.

Specifically, 94% of 43 executives queried project product launches will be delayed by a year or more, and 35% indicated delays already occurred. Meanwhile, 90% maintained the pricing reforms will hurt R&D, and one-third of the executives indicated staffing was already effected, but a specific number of job losses were not mentioned in the survey issued by Life Sciences Ontario.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!